UBS AM
ICPT

UBS AM’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

UBS AM’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-23,834
Closed -$442K – 2633
2023
Q3 		$442K Hold
23,834
– – ﹤0.01% 2341
2023
Q2 		$320K Hold
23,834
– – ﹤0.01% 2457
2023
Q1 		$320K Sell
23,834
-3,745
-14% -$64.8K ﹤0.01% 2457
2022
Q4 		$341K Buy
27,579
+14,948
+118% +$212K ﹤0.01% 2306
2022
Q3 		$176K Sell
12,631
-10,792
-46% -$174K ﹤0.01% 2626
2022
Q2 		$323K Sell
23,423
-1,686
-7% -$27K ﹤0.01% 2454
2022
Q1 		$409K Hold
25,109
– – ﹤0.01% 2528
2021
Q4 		$409K Hold
25,109
– – ﹤0.01% 2618
2021
Q3 		$373K Hold
25,109
– – ﹤0.01% 2582
2021
Q2 		$501K Buy
25,109
+12,478
+99% +$247K ﹤0.01% 2536
2021
Q1 		$292K Hold
12,631
– – ﹤0.01% 2491
2020
Q4 		$312K Sell
12,631
-147,885
-92% -$4.9M ﹤0.01% 2403
2020
Q3 		$6.65M Sell
160,516
-5,750
-3% -$264K ﹤0.01% 1058
2020
Q2 		$7.97M Sell
166,266
-2,243
-1% -$173K ﹤0.01% 974
2020
Q1 		$10.6M Sell
168,509
-14,696
-8% -$1.32M 0.01% 848
2019
Q4 		$22.7M Buy
183,205
+24,066
+15% +$2.15M 0.01% 740
2019
Q3 		$10.6M Buy
159,139
+2,098
+1% +$141K 0.01% 936
2019
Q2 		$12.5M Buy
157,041
+61,017
+64% +$5.46M 0.01% 890
2019
Q1 		$10.7M Buy
96,024
+2,946
+3% +$322K 0.01% 912
2018
Q4 		$9.38M Sell
93,078
-23,037
-20% -$2.39M 0.01% 895
2018
Q3 		$14.7M Buy
116,115
+105,719
+1,017% +$11.2M 0.01% 841
2018
Q2 		$872K Buy
10,396
+716
+7% +$52.4K ﹤0.01% 1865
2018
Q1 		$596K Hold
9,680
– – ﹤0.01% 1966
2017
Q4 		$566K Buy
9,680
+455
+5% +$28.7K ﹤0.01% 1929
2017
Q3 		$535K Sell
9,225
-142,138
-94% -$15.3M ﹤0.01% 1922
2017
Q2 		$18.3M Sell
151,363
-5,844
-4% -$677K 0.02% 765
2017
Q1 		$17.8M Buy
157,207
+25,607
+19% +$2.99M 0.02% 754
2016
Q4 		$14.3M Sell
131,600
-4,020
-3% -$479K 0.02% 783
2016
Q3 		$22.3M Sell
135,620
-2,497
-2% -$394K 0.02% 642
2016
Q2 		$19.7M Sell
138,117
-4,468
-3% -$651K 0.02% 682
2016
Q1 		$18.3M Buy
142,585
+5,843
+4% +$690K 0.02% 692
2015
Q4 		$20.4M Buy
136,742
+116
+0.1% +$19.6K 0.02% 663
2015
Q3 		$22.7M Sell
136,626
-11,362
-8% -$2.5M 0.03% 640
2015
Q2 		$35.7M Buy
147,988
+19,463
+15% +$5.18M 0.03% 522
2015
Q1 		$36.2M Buy
128,525
+6,100
+5% +$1.32M 0.03% 513
2014
Q4 		$19.1M Buy
122,425
+29,300
+31% +$5.41M 0.02% 713
2014
Q3 		$22M Buy
93,125
+3,925
+4% +$1M 0.02% 653
2014
Q2 		$21.1M Buy
89,200
+7,000
+9% +$1.84M 0.02% 662
2014
Q1 		$27.1M Sell
82,200
-26,300
-24% -$8.87M 0.03% 568
2013
Q4 		$7.41M Buy
+108,500
New +$6.27M 0.01% 908

UBS AM's ICPT Position: Q4 2023 in Review

UBS AM sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 23,834 shares — an estimated $442K sold.

UBS AM first reported a position in ICPT in Q4 2013 and held it in 40 quarters. The position peaked at $36.2M in Q1 2015. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.

  • UBS AM reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
  • UBS AM sold 23,834 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $442K.
  • UBS AM first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2013 and held it in 40 quarters.
  • UBS AM's Intercept Pharmaceuticals, Inc. position peaked at $36.2M in Q1 2015.
  • 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.

Based on UBS AM's 13F filing for Q4 2023, filed 14 Feb 2024.